



## Comparison between Systematic and MRI Targeted Prostate Biopsy for patient with no history of prostate cancer attending a first round of trans-rectal ultrasound biopsy procedure

Coffin G<sup>1,2</sup>, Chevreau G<sup>1</sup>, Renard-Penna R<sup>3</sup>, Comperat E<sup>4</sup>, Vitrani MA<sup>2</sup>, Torterotot C<sup>2</sup>, Conort P<sup>1</sup>, Bitker MO<sup>1</sup>, Mozer P<sup>1,2</sup>

<sup>1</sup>Academic Department of Urology, La Pitié-Salpêtrière hospital, Assistance-Publique Hôpitaux de Paris, Paris, France

<sup>2</sup>SIR laboratory, University Pierre and Marie Curie, CNRS-UMR7222, Paris, France

<sup>3</sup>Academic Department of Radiology, La Pitié-Salpêtrière hospital, Assistance-Publique Hôpitaux de Paris, Paris, France

<sup>4</sup>Academic Department of Anatomopathology, La Pitié-Salpêtrière hospital, Assistance-Publique Hôpitaux de Paris, Paris, France

**Objective:** to compare the effectiveness of systematic biopsies and MRI targeted biopsies for a first round of prostate biopsy procedure among a population of men at risk of localized prostate cancer with no history of prostate cancer.

**Methods:** We retrospectively reviewed all patients who came at our department for a first round of prostate biopsies and who were at risk of localized prostate cancer.

**Exclusion criteria** were: **history of prostate cancer**, previous prostate **biopsy**, **local advanced** ( $\geq T3a$  TNM stage) or **metastatic** prostate cancer at examination (digital rectal and clinical examination, PSA serum level  $> 20$  ng/mL, prostate MRI staging  $\geq T3a$ ).

**Inclusion criteria** were: prostate multiparametric **MRI** showing suspicious intra-prostatic **lesion**.

All patients attended trans-rectal ultrasound biopsies with a Medison V10 Ultrasound system and the Urostation® registration device (Koelis, France): **12 systematic cores** were realized and **2 or 3 additional** cores in the **MRI targeted lesion**

Positive core was defined by the presence of prostate cancer on anatomopathological examination.

### Results :

Number of patients	80
Age (years)	63.9 $\pm$ 7.34[49.9;81.2]
Prostate Volume (mL)	44 $\pm$ 22[17;160]
Suspicious DRE	20
PSA serum level (ng/mL)	7.85 $\pm$ 3.45[2.8;20]

**Table 1.** Patients Characteristics. Results are showed as Mean $\pm$ Sd[Range] . DRE: Digital Rectal Examination

	Systematic Biopsies	MRI Targeted Biopsies	p
Number of cores	948	201	
Number of positive cores	158	77	
% of Positive cores (number)	16.67%	38.31%	<0.001
Cancer mean length by core (mm)	6.72	8.93	0.002

**Table 2.** Anatomopathological results of prostate biopsy cores.

### Conclusion:

**MRI targeted cores** seem to be **more accurate** than systematic cores to detect localized prostate cancer and could prevent the use of systematic prostate biopsies to detect cancer and consequently **decrease the number of cores** for a prostate biopsy diagnosis procedure.